List of Publications

Michael Asger Andersen, MD, PhD

Specialty Registrar, Department of Clinical Pharmacology

Copenhagen University Hospital, Bispebjerg and Frederiksberg

ORCID: 0000-0001-9729-9974 · Updated: October 2026

Summary Metrics (October 2026)

- **Total Peer-Reviewed Publications:** 46 articles (44 international journals, 2 in *Ugeskrift for Læger*; plus 1 case report)
- **Author Roles:** First author (13) · Senior / last author (5) · Co-author (28)
- **Citations & Metrics:** 1,112 citations (1,012 since 2021) · H-index: 18 (17 since 2021) · i10-index: 27 (26 since 2021; Source: Google Scholar, 29 October 2026)
- **Open Access:** Over 85% open access
- Asterisk (*) indicates 10 selected major publications.

I. Original Scientific Publications (Peer-Reviewed)

1. * **Andersen MA**, Vojdeman FJ, Andersen MK, Brown Pde N, Geisler CH, Weis Bjerrum O, Niemann CU. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. *Leuk Lymphoma*. 2016;57(7):1592–9.
2. Johansen MM, **Andersen MA**, Grønbaek K, Hansen JW. Long-term clinical outcomes of patients with hematologically unexplained cytopenia after routine assessment: A single center study. *Eur J Haematol*. 2018;101(5):595–603.
3. **Andersen MA**, Bjerrum OW, Ranjan A, Skov V, Kruse TA, Thomassen M, . . . , Christensen K. Myeloproliferative Neoplasms in Danish Twins. *Acta Haematol*. 2018;139(3):195–198.
4. Brieghel C, Kinalis S, Yde CW, Schmidt AY, Jønson L, **Andersen MA**, . . . , Niemann CU. Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact in the era of targeted therapy. *Haematologica*. 2019;104(4):789–796.
5. * **Andersen MA**, Moser CE, Lundgren J, Niemann CU. Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study. *Leukemia*. 2019;33(3):662–670. *(Erratum: Leukemia. 2020;34(10):2817–2818).*
6. Hleuhel MH, Ben-Dali Y, Da Cunha-Bang C, Brieghel C, Clasen-Linde E, Niemann CU, **Andersen MA**. Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study. *BMJ Open*. 2019;9(3):e023566.
7. Agius R, Brieghel C, **Andersen MA**, Pearson AT, Ledergerber B, Cozzi-Lepri A, . . . , Niemann CU. Machine learning can identify newly diagnosed patients with CLL at high risk of infection. *Nat Commun*. 2020;11(1):363.
8. Aarup K, Rotbain EC, Enggaard L, Pedersen RS, Bergmann OJ, Thomsen RH, . . . , Niemann CU. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. *Eur J Haematol*. 2020;105(5):646–654.
9. Ben-Dali Y, Hleuhel MH, da Cunha-Bang C, Brieghel C, Poulsen CB, Clasen-Linde E, . . . , **Andersen MA**. Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. *Leuk Lymphoma*. 2020;61(6):1435–1444.
10. * Brieghel C, da Cunha-Bang C, Yde CW, Schmidt AY, Kinalis S, Nadeu F, . . . , Niemann CU. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome. *Clin Cancer Res*. 2020;26(6):1507–1515.
11. **Andersen MA**, Rostgaard K, Niemann CU, Hjalgrim H. Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study. *Leukemia*. 2021;35(3):747–751.
12. Brieghel C, Aarup K, Torp MH, **Andersen MA**, Yde CW, Tian X, . . . , Niemann CU. Clinical and

Biological Implications of Multi-Hit Versus Single-Hit TP53 Inactivation in Chronic Lymphocytic Leukemia. *Clin Cancer Res*. 2021;27(16):4531–4538.

13. * **Andersen MA**, Niemann CU, Rostgaard K, Dalby T, Sørrig R, Weinberger DM, Hjalgrim H, Harboe ZB. Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study. *Clin Infect Dis*. 2021;72(3):463–471.
14. Rotbain EC, Rostgaard K, **Andersen MA**, Da Cunha-Bang C, Niemann CU, Frederiksen H, Hjalgrim H. Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia. *Clin Epidemiol*. 2021;13:1155–1165.
15. da Cunha-Bang C, Rostgaard K, **Andersen MA**, Rotbain EC, Grønbaek K, Frederiksen H, Niemann CU, Hjalgrim H. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study. *Br J Haematol*. 2021;193(2):339–345.
16. Davidsson OB, Olofsson IA, Kogelman LJ, **Andersen MA**, Rostgaard K, Hjalgrim H, Olesen J, Hansen TF. Twenty-five years of triptans - a nationwide population study. *Cephalalgia*. 2021;41(8):894–904.
17. Svanberg R, MacPherson C, Zucco A, Agius R, Faitova T, **Andersen MA**, . . . , Ostrowski SR. Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients. *Commun Med (Lond)*. 2022;2:114. *(Author Correction: Commun Med. 2023;3:15)*.
18. Staerk-Østergaard J, Kirkeby C, Christiansen LE, **Andersen MA**, Møller CH, Voldstedlund M, Denwood MJ. Evaluation of diagnostic test procedures for SARS-CoV-2 using latent class models. *J Med Virol*. 2022;94(10):4754–4761.
19. Brieghel C, Galle V, Agius R, da Cunha-Bang C, **Andersen MA**, Vlummens P, . . . , Niemann CU. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. *Eur J Haematol*. 2022;108(5):369–378.
20. * **Andersen MA**, Grand MK, Brieghel C, Siersma V, Andersen CL, Niemann CU. Pre-diagnostic trajectories of lymphocytosis predict time to treatment and death in patients with chronic lymphocytic leukemia. *Commun Med (Lond)*. 2022;2:50.
21. Nielsen KF, Moustsen-Helms IR, Schelde AB, Gram MA, Emborg HD, Nielsen J, . . . , Valentiner-Branth P. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. *PLoS Med*. 2022;19(11):e1004037.
22. Rotbain EC, Allmer C, Rostgaard K, **Andersen MA**, Vainer N, da Cunha-Bang C, . . . , Niemann CU. Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia. *Am J Hematol*. 2023;98(8):1236–1245.
23. Roen A, Terrones C, Bannister W, Helleberg M, **Andersen MA**, Niemann CU, . . . , Lundgren J. Increased incidence rates of positive blood cultures shortly after chemotherapy compared to radiotherapy among individuals treated for solid malignant tumours. *Infection*. 2023;51(1):147–157.
24. Vainer N, Aarup K, **Andersen MA**, Wind-Hansen L, Nielsen T, Frederiksen H, . . . , Rotbain EC. Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia. *Br J Haematol*. 2023;201(5):874–886.
25. * **Andersen MA**, Helms Andreasen A, Evi Bang L, Jimenez-Solem E, Petersen TS. A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia. *Commun Med (Lond)*. 2024;4(1):193.
26. * **Andersen MA**, Gregersen R, Petersen TS, Wang JN, Petersen J, Jimenez-Solem E. Association Between First-time Neurologic Events and Metronidazole Treatment: A Case-time Control Study. *Clin Ther*. 2024;46(4):307–312.
27. * **Andersen MA**, Jensen TL, Petersen TS. Data Resource Profile: The Danish National Hospital Medicine Register. *Pharmacoepidemiol Drug Saf*. 2024;33(11):e70054.
28. Packness E, Davidsson OB, Rostgaard K, **Andersen MA**, Rotbain EC, Niemann CU, Brieghel C, Hjalgrim H. Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma. *Br J Cancer*. 2024;131(7):1186–1194.

29. * Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, **Andersen MA**, Johansson KS, . . . , Horwitz H. Cardiovascular Disease in Anabolic Androgenic Steroid Users. *Circulation*. 2025;151(12):828–834.
30. Brieghel C, Lacoppidan T, Packness E, Frederiksen CM, Werling M, **Andersen MA**, . . . , Niemann CU. Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer. *Hemasphere*. 2025;9(7):e70172.
31. Christensen LWS, Boas AK, Clausen E, Koch NE, Walls AB, Nørgaard LS, . . . , Houlind MB. Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients. *Br J Clin Pharmacol*. 2026;10.1002/bcp.70799.

II. Clinical Guidelines & Consortia (Peer-Reviewed)

32. Eadon MT, Hein DW, **Andersen MA**, Chapman AB, Cooper-DeHoff RM, Desta Z, . . . , Agúndez JAG. Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. *Clin Pharmacol Ther*. 2025;118(6):1430–1436.

III. Scientific Reviews (Peer-Reviewed)

33. Del Giudice I, Cappelli LV, Delgado J, Niemann CU, **Andersen MA**, Rotbain EHC, . . . , Foà R. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature. *Br J Haematol*. 2023;201(2):353–356.
34. Karlsen APH, Sunde PB, Olsen MH, Laigaard J, Folkersen C, Tran TXM, . . . , Mathiesen O. Opioids and personalized analgesia in the perioperative setting: A protocol for five systematic reviews. *Acta Anaesthesiol Scand*. 2024;68(10):1573–1580.
35. Erichsen PA, Dalhoff K, **Andersen MA**. Should high-dose N-acetylcysteine be given in cases of massive paracetamol overdoses: A narrative review. *Basic Clin Pharmacol Toxicol*. 2024;135(3):285–294.
36. Korsholm C, Bülow C, Christensen M, Dalhoff K, Feinberg JB, Lund TM, . . . , **Andersen MA**. Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review. *Leuk Lymphoma*. 2025;66(2):229–239.
37. Breining P, Bork CS, Bartels LE, **Andersen MA**. Statin-induced muscle symptoms. *Ugeskr Laeger*. 2025;187(43):V03250169.
38. Kjartansdóttir SP, Folkersen C, Rasmussen IH, Sunde PB, Saito A, Maagaard M, . . . , Karlsen APH. Pharmacogenetic Predictors of Postoperative Opioid-Related Adverse Events: A Systematic Review. *Basic Clin Pharmacol Toxicol*. 2026;138(2):e70154.
39. Bentsen MS, Bundgaard JS, Brøns N, Rand SA, **Andersen MA**, Rossing M, . . . , Ostrowski SR. Clinical pharmacogenetics and the use of biobanks. *Ugeskr Laeger*. 2026;188(37):V01260062.

IV. Short Reports, Commentaries & Other Peer-Reviewed Publications

40. **Andersen MA**, Nielsen RT. Spontaneous renal rupture of fornix due to obstructing urethral stone. *Ugeskr Laeger*. 2017;179(36):V02170114.
41. **Andersen MA**, Niemann CU. Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark. *Haematologica*. 2018;103(7):e330.
42. * **Andersen MA**, Eriksen CT, Brieghel C, Biccler JL, Cunha-Bang CD, Helleberg M, Niemann CU. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. *Haematologica*. 2018;103(7):e300–e303.
43. **Andersen MA**, Valentin R, Dissing Sjö L, Borgwardt L, Schmiegelow K, Andersen MK, . . . , Niemann CU. Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma. *Acta Oncol*. 2020;59(12):1547–1551.

44. Egholm GJ, **Andersen MA**, Andersen CL, Frederiksen H, Bjerrum OW, Niemann CU. Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival. *Br J Haematol*. 2021;192(3):e81–e84.

45. Vojdeman FJ, Helby J, Pedersen LB, Brieghel C, **Andersen MA**, Nordestgaard BG, Bojesen SE, Niemann CU. Chronic lymphocytic leukaemia clones are detectable decades before diagnosis. *Br J Haematol*. 2022;196(3):784–787.

46. Damkier P, **Andersen MA**. Temporary Like Achilles: Pre-emptive germline pharmacogenetic testing. *Basic Clin Pharmacol Toxicol*. 2023;133(4):397–399.

47. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, **Andersen MA**, Johansson KS, ..., Horwitz H. Response by Windfeld-Mathiasen et al to Letter Regarding Article, "Cardiovascular Disease in Anabolic Androgenic Steroid Users". *Circulation*. 2025;152(16):e296–e297.

V. PATENTS

None.